MedPath

D-chiro Inositol in Prevention of Gestational Diabetes Mellitus in China

Not Applicable
Completed
Conditions
Gestational Diabetes Mellitus in Pregnancy
Registration Number
NCT04801485
Lead Sponsor
Women's Hospital School Of Medicine Zhejiang University
Brief Summary

Inositol is a type of food additives, which plays an important role in insulin signal pathway and is related to insulin sensitivity. Our randomized, double-centered, placebo-controlled study is planned to recruit 360 pregnant women who is in high risk for gestational diabetes. They will be assumed randomly 1 g of D-chiro inositol per day or placebo from 12-16th gestational weeks until Oral Glucose Tolerance Test (OGTT) at 24-28th gestational weeks. Perinatal outcomes about delivery time, neonatal weight will be registered.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
291
Inclusion Criteria
  • During 12-16 weeks gestation
  • Meet any of the following: prepregnancy BMI > 24, family history of diabetes (type 1 or 2), GDM history, history of delivering macrosomia, gestational history of stillbirth;
  • Willing to participate
Exclusion Criteria
  • Type 1 or type 2 diabetes mellitus diagnosed before pregnancy
  • Multiple gestation
  • Mental or cognitive impairment cannot complete the study

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
the incidence of gestational diabetes24-28th weeks gestation

The number of cases and incidence of gestational diabetes according to OGTT

Secondary Outcome Measures
NameTimeMethod
the perinatal outcomes-2Delivery

weight gain during pregnancy (kg)

the perinatal outcomes-3Delivery

the Caesarean-section incidence (%)

the perinatal outcomes-1Delivery

the incidence of macrosomia (macrosomia refers to a newborn weighs more than 4 kg)

Trial Locations

Locations (1)

Xinning Chen

🇨🇳

Hangzhou, Zhejiang, China

Xinning Chen
🇨🇳Hangzhou, Zhejiang, China

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.